한글목차

처방 피부과 치료제 시장 규모는 2025년 567억 5,000만 달러에서 2034년에는 1,255억 달러에 달할 것으로 예측되며, 2026년부터 2034년까지 CAGR 9.22%로 성장할 전망입니다.

피부질환의 유병률 증가와 효과적인 치료법에 대한 수요 증가로 인해 처방용 피부치료제 시장은 큰 폭의 성장이 예상됩니다. 건선, 습진, 여드름, 피부암과 같은 질환이 점점 더 흔해짐에 따라 의료진은 이러한 문제를 해결할 수 있는 혁신적인 피부 치료법을 모색하고 있습니다. 시장에서는 기존 치료법에 비해 개선된 효능과 안전성 프로파일을 제공하는 생물학적 제제 및 표적 치료제의 개발이 급증하고 있습니다. 이러한 발전은 장기적인 치료가 필요한 만성 피부 질환 관리에서 특히 중요합니다.

또한, 맞춤형 의료에 대한 관심이 높아진 것도 처방 피부과 치료제 시장에 영향을 미치고 있습니다. 의료진들이 환자 개개인의 필요에 맞춘 치료의 중요성을 점점 더 인식함에 따라 유전적 요인과 환경적 요인을 고려한 치료법에 대한 수요가 증가하고 있습니다. 이러한 추세는 치료 방침을 결정하고 환자의 치료 결과를 개선할 수 있는 특정 바이오마커를 식별하기 위한 연구개발 노력을 촉진하고 있습니다. 또한, 원격 피부과 진료 및 모바일 헬스 애플리케이션과 같은 디지털 헬스 기술의 통합으로 피부과 의료에 대한 접근성이 향상되고 치료 효과에 대한 원격 모니터링이 용이해졌습니다.

또한, 피부 건강에 대한 인식 개선 및 지원 활동의 증가도 처방 피부과 치료제 시장의 성장에 기여하고 있습니다. 소비자들이 피부 질환과 치료 옵션에 대해 더 많은 정보를 얻게 됨에 따라, 의료 상담을 받고 효과적인 치료를 추구하는 경향이 증가하고 있습니다. 제약사, 의료 서비스 제공자, 환자 지원 단체 간의 협력은 혁신을 촉진하고 피부 치료에 대한 접근성을 확대하고 있습니다. 요약하면, 처방 피부과 치료제 시장은 기술 발전, 맞춤형 의료에 대한 관심, 피부 질환을 앓고 있는 개인의 삶의 질 향상에 대한 노력으로 인해 견조한 성장이 예상됩니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 처방 피부과 치료제 시장 : 제품 유형별

제5장 세계의 처방 피부과 치료제 시장 : 유통 채널별

제6장 세계의 처방 피부과 치료제 시장 : 지역별

제7장 경쟁 구도

제8장 기업 개요

영문목차

The Prescription Dermatology Therapeutics Market size is expected to reach USD 125.50 Billion in 2034 from USD 56.75 Billion (2025) growing at a CAGR of 9.22% during 2026-2034.

The prescription dermatology therapeutics market is poised for significant growth, driven by the increasing prevalence of skin disorders and the rising demand for effective treatment options. As conditions such as psoriasis, eczema, acne, and skin cancer become more common, healthcare providers are seeking innovative dermatological therapies to address these challenges. The market is witnessing a surge in the development of biologics and targeted therapies that offer improved efficacy and safety profiles compared to traditional treatments. These advancements are particularly relevant in the management of chronic skin conditions, where long-term treatment is often necessary.

Moreover, the growing emphasis on personalized medicine is influencing the prescription dermatology therapeutics market. As healthcare providers increasingly recognize the importance of tailoring treatments to individual patient needs, the demand for therapies that consider genetic and environmental factors is rising. This trend is driving research and development efforts aimed at identifying specific biomarkers that can guide treatment decisions and improve patient outcomes. Additionally, the integration of digital health technologies, such as teledermatology and mobile health applications, is enhancing access to dermatological care and facilitating remote monitoring of treatment efficacy.

Furthermore, the rise of awareness campaigns and advocacy for skin health is contributing to the growth of the prescription dermatology therapeutics market. As consumers become more informed about skin conditions and available treatment options, they are more likely to seek medical advice and pursue effective therapies. The collaboration between pharmaceutical companies, healthcare providers, and patient advocacy groups is fostering innovation and expanding access to dermatological treatments. In summary, the prescription dermatology therapeutics market is set for robust growth, characterized by technological advancements, a focus on personalized care, and a commitment to improving the quality of life for individuals with skin disorders.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Acne & Rosacea Drugs
• Psoriasis Drugs
• Dermatitis & Seborrhea Drugs
• Fungal Infection Drugs
• Skin Cancer Drugs
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Mail Order Pharmacies

COMPANIES PROFILED

• AbbVie Inc, Janssen Biotech Inc, Novartis AG, Amgen Inc, Celgene Corporation, Pfizer Inc, LEO Pharma AS, Eli Lilly and Company, Bausch Health Companies Inc, Sun Pharmaceuticals Ltd, Aclaris Therapeutics Inc, Aurobindo Pharma Ltd

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Acne & Rosacea Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Psoriasis Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Dermatitis & Seborrhea Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Fungal Infection Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Skin Cancer Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Mail Order Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product Type
  • 6.2.2 By Distribution Channel
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product Type
  • 6.3.2 By Distribution Channel
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product Type
  • 6.4.2 By Distribution Channel
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product Type
  • 6.5.2 By Distribution Channel
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product Type
  • 6.6.2 By Distribution Channel
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 AbbVie Inc
  • 8.2.2 Janssen Biotech Inc
  • 8.2.3 Novartis AG
  • 8.2.4 Amgen Inc
  • 8.2.5 Celgene Corporation
  • 8.2.6 Pfizer Inc
  • 8.2.7 LEO Pharma A/S
  • 8.2.8 Eli Lilly And Company
  • 8.2.9 Bausch Health Companies Inc
  • 8.2.10 Sun Pharmaceuticals Ltd
  • 8.2.11 Aclaris Therapeutics Inc
  • 8.2.12 Aurobindo Pharma Ltd